Given Trop-2’s regulatory role in cervical cancer progression and host immune responses, clinical trials have been initiated to evaluate the efficacy and safety of combining Trop-2-directed ADCs with ICIs. This evidence concerns the gene TACSTD2 and cervical carcinoma.